Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
61.05
-0.27 (-0.44%)
Aug 10, 2026, 2:23 PM EDT - Market open
Travere Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $72.79. The average 1-year stock price forecast is 19.23% higher than the current stock price, while the lowest is $49 (-19.74%) and the highest is $90 (+47.42%).
Price Target: $72.79 (+19.23%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Reiterates $68 → $78 | Buy | Reiterates | $68 → $78 | +27.76% | Aug 10, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $43 → $62 | Hold | Maintains | $43 → $62 | +1.56% | Aug 9, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $53 → $90 | Buy | Maintains | $53 → $90 | +47.42% | Aug 7, 2026 |
| Wedbush | Wedbush | Buy Maintains $61 → $75 | Buy | Maintains | $61 → $75 | +22.85% | Aug 6, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $65 → $80 | Buy | Maintains | $65 → $80 | +31.04% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
719.17M
from 490.73M
Increased by 46.55%
Revenue Next Year
1.07B
from 719.17M
Increased by 48.70%
EPS This Year
1.76
from 0.91
Increased by 93.30%
EPS Next Year
5.44
from 1.76
Increased by 209.32%
EPS and Forward PE are based on non-GAAP adjusted numbers.